471 related articles for article (PubMed ID: 12469179)
1. Chemoprevention of prostate cancer by diet-derived antioxidant agents and hormonal manipulation (Review).
Pathak SK; Sharma RA; Mellon JK
Int J Oncol; 2003 Jan; 22(1):5-13. PubMed ID: 12469179
[TBL] [Abstract][Full Text] [Related]
2. Update on prostate cancer chemoprevention.
Lowe JF; Frazee LA
Pharmacotherapy; 2006 Mar; 26(3):353-9. PubMed ID: 16503715
[TBL] [Abstract][Full Text] [Related]
3. Chemoprevention of prostate cancer: agents and study designs.
Thompson IM
J Urol; 2007 Sep; 178(3 Pt 2):S9-S13. PubMed ID: 17644117
[TBL] [Abstract][Full Text] [Related]
4. Risk biomarkers and current strategies for cancer chemoprevention.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
[TBL] [Abstract][Full Text] [Related]
5. [Nutrition and pharmacological treatment for prevention of prostate cancer].
Segev Y; Nativ O
Harefuah; 2006 Jan; 145(1):47-51, 76-7. PubMed ID: 16450727
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of disease: Prostate cancer--a model for cancer chemoprevention in clinical practice.
Canby-Hagino ED; Thompson IM
Nat Clin Pract Oncol; 2005 May; 2(5):255-61. PubMed ID: 16264961
[TBL] [Abstract][Full Text] [Related]
7. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
[TBL] [Abstract][Full Text] [Related]
8. Chemoprevention of prostate cancer.
Stephenson AJ; Abouassaly R; Klein EA
Urol Clin North Am; 2010 Feb; 37(1):11-21, Table of Contents. PubMed ID: 20152515
[TBL] [Abstract][Full Text] [Related]
9. Lycopene as a chemopreventive agent in the treatment of high-grade prostate intraepithelial neoplasia.
Mohanty NK; Saxena S; Singh UP; Goyal NK; Arora RP
Urol Oncol; 2005; 23(6):383-5. PubMed ID: 16301113
[TBL] [Abstract][Full Text] [Related]
10. Chemoprevention of prostate cancer through dietary agents: progress and promise.
Syed DN; Khan N; Afaq F; Mukhtar H
Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2193-203. PubMed ID: 18006906
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer chemoprevention.
Sandhu GS; Nepple KG; Tanagho YS; Andriole GL
Semin Oncol; 2013 Jun; 40(3):276-85. PubMed ID: 23806493
[TBL] [Abstract][Full Text] [Related]
12. Target populations and strategies for chemoprevention trials of prostate cancer.
Bostwick DG
J Cell Biochem Suppl; 1994; 19():191-6. PubMed ID: 7823591
[TBL] [Abstract][Full Text] [Related]
13. Can we prevent prostate cancer? Rationale and current status of prostate cancer chemoprevention.
Fujimoto N; Chang C; Nomura M; Matsumoto T
Urol Int; 2005; 74(4):289-97. PubMed ID: 15897691
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer chemoprevention: current status and future prospects.
Gupta S
Toxicol Appl Pharmacol; 2007 Nov; 224(3):369-76. PubMed ID: 17189645
[TBL] [Abstract][Full Text] [Related]
15. Lycopene in the prevention of prostate cancer.
Dahan K; Fennal M; Kumar NB
J Soc Integr Oncol; 2008; 6(1):29-36. PubMed ID: 18302908
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological approaches to reducing the risk of prostate cancer.
Rittmaster RS; Fleshner NE; Thompson IM
Eur Urol; 2009 May; 55(5):1064-73. PubMed ID: 19200641
[TBL] [Abstract][Full Text] [Related]
17. High-grade prostatic intraepithelial neoplasia as an exposure biomarker for prostate cancer chemoprevention research.
Marshall JR
IARC Sci Publ; 2001; 154():191-8. PubMed ID: 11220658
[TBL] [Abstract][Full Text] [Related]
18. Prostate cells exposed to lycopene in vitro liberate lycopene-enriched exosomes.
Goyal A; Delves GH; Chopra M; Lwaleed BA; Cooper AJ
BJU Int; 2006 Oct; 98(4):907-11. PubMed ID: 16978292
[TBL] [Abstract][Full Text] [Related]
19. Impact of diet on prostate cancer: a review.
Sonn GA; Aronson W; Litwin MS
Prostate Cancer Prostatic Dis; 2005; 8(4):304-10. PubMed ID: 16130015
[TBL] [Abstract][Full Text] [Related]
20. Open to debate. The motion: prevention of prostate cancer with a 5alpha-reductase inhibitor is feasible.
Roehrborn CG; Lotan Y; Tubaro A; de Nunzio C
Eur Urol; 2006 Feb; 49(2):396-400. PubMed ID: 16455190
[No Abstract] [Full Text] [Related]
[Next] [New Search]
